Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

Eli Lilly on Thursday said its blockbuster diabetes drug Mounjaro showed heart health benefits in a late-stage trial directly comparing it to the company's older diabetes treatment, Trulicity ...

Collaboration combines LTZ’s first-in-class Myeloid Engager Platform with Lilly’s world-class expertise in research, development and commercialization LTZ Therapeutics (“LTZ”), an ...

Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index.

Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company ...

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts.

Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast cancer awareness activations.